Coronary Artery Disease

While not meeting a performance goal, genetic screening of patients with ACS or stable CAD after PCI to guide antiplatelet therapy choice numerically reduced serious adverse CV events, according to the results of the TAILOR PCI trial.

Fewer than half of patients with new-onset HF are tested for CAD, and even fewer are tested during their index hospitalization.

CAD, despite the success of secondary prevention, is pandemic and the leading cause of death in high-, middle- and low-income countries throughout the world.

Two polygenic risk scores, one for predicting CHD and one for predicting CAD, did not meaningfully improve risk prediction beyond conventional risk factors, according to findings published in JAMA.

Electrocardiographic and biochemical signatures with ECG or alone to detect exercise-induced myocardial ischemia in patients with CAD.

Among patients who underwent PCI or CABG between 2003 and 2016, risk-adjusted mortality decreased in the CABG population but not in the PCI population over time, researchers reported in JAMA Network Open.

The risk for coronary artery disease may be lower among those with diabetes who have elevated vs. lower immature platelet fraction, although glucose management is unaffected by this biomarker, according to findings published in Diabetes/Metabolism Research and Reviews.

The longitudinal increase of HbA1c was found to be independently associated with elevated incidence of CV events for patients with diabetes and multivessel CAD, according to findings published in JAMA Network Open.

Routine use of fractional flow reserve to manage CAD among patients with diabetes may be linked to an increased rate of treatment reclassification, according to a study published in JAMA Cardiology.

Very low concentrations of high-sensitivity cardiac troponin did not allow the safe exclusion of inducible myocardial ischemia, according to a study published in the Annals of Internal Medicine.